Lupin shares surge nearly 2% after launching generic Glucagon for Injection in the US

Shares of Lupin soared 1.7% to an intra-day high of ₹1,950.70 apiece on the National Stock Exchange (NSE) on Monday, August 11. This comes after the drug maker announced the launch of a medication,used to regulate blood glucose levels, in the US market.

The pharma major launched Glucagon for Injection USP, 1mg per vial packaged in an emergency kit in the US, the Mumbai-based company said in a regulatory filing.

The pharmaceutical's product is a bioequivalent to Eli Lilly and Lupin’s Glucagon for injection, 1 mg per vial, it added.

Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus (or just diabetes) and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract (also known as digestive tract) in adult patients.

As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of $122 million in the US.

Lupin Q1 results

The drug marker reported a 77% year-on-year (YoY) rise in its consolidated net profit to ₹801 crore in the June quarter of FY26, compared to ₹452 crore in the same period a year ago.

The company’s total revenue from operations surged 16.3% YoY to ₹5,600 crore during the quarter under review, as against ₹4,814 crore in the first quarter of FY25.

At an operating level, its EBITDA (earnings before interest, tax, depreciation and amortisation) was up by 22.9% YoY at ₹1,240.9 crore in Q1FY26, compared to ₹856.3 crore in the corresponding period a year earlier.

During the reporting quarter, Lupin invested 6.3% of its sales (equivalent to ₹350 crore) in research and development. While its formulation sales in North America surged 28.3% YoY ₹2,040.8 crore, domestic sales grew by 17.5% to ₹1,925.9 crore.

Its total US sales rose to $227 million, up from $181 million a year ago and $209 million in the previous quarter.

Commenting on the earnings, Nilesh Gupta, Managing Director at Lupin, said: “We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth.”

At around 3 pm, the Lupin stock was trading 1.7% higher at ₹1,950.60 per equity share.